Page last updated: 2024-08-24

3-iodobenzylguanidine and Hematologic Malignancies

3-iodobenzylguanidine has been researched along with Hematologic Malignancies in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Batra, V; DuBois, SG; Fetzko, S; Huibregtse, KE; Marachelian, A; Maris, JM; Matthay, KK; Neuhaus, J; Vo, KT; Weiss, B; Yanik, GA	1
Bodei, L; Brans, B; Giammarile, F; Luster, M; Maecke, HR; Oyen, WJ; Tennvall, J	1
Franzius, C; Hahn, K; Hero, B; Pfluger, T; Schmidt, M	1

Reviews

1 review(s) available for 3-iodobenzylguanidine and Hematologic Malignancies

Article	Year
Targeted therapy in nuclear medicine--current status and future prospects. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:11 Topics: 3-Iodobenzylguanidine; Female; Forecasting; Hematologic Neoplasms; Humans; Indium Radioisotopes; Male; Neoplasms; Neuroblastoma; Nuclear Medicine; Ovarian Neoplasms; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Risk Assessment; Survival Analysis; Thyroid Neoplasms; Treatment Outcome	2007

Article

Year

Targeted therapy in nuclear medicine--current status and future prospects.

Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:11

Topics: 3-Iodobenzylguanidine; Female; Forecasting; Hematologic Neoplasms; Humans; Indium Radioisotopes; Male; Neoplasms; Neuroblastoma; Nuclear Medicine; Ovarian Neoplasms; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Risk Assessment; Survival Analysis; Thyroid Neoplasms; Treatment Outcome

2007

Trials

1 trial(s) available for 3-iodobenzylguanidine and Hematologic Malignancies

Article	Year
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. European journal of cancer (Oxford, England : 1990), 2016, Volume: 66 Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Female; Hematologic Neoplasms; Humans; Infant; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neuroblastoma; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Young Adult	2016

Article

Year

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.

European journal of cancer (Oxford, England : 1990), 2016, Volume: 66

Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Female; Hematologic Neoplasms; Humans; Infant; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neuroblastoma; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Young Adult

2016

Other Studies

1 other study(ies) available for 3-iodobenzylguanidine and Hematologic Malignancies

Article	Year
[Procedure guidelines for MIBG-scintigraphy in children]. Nuklearmedizin. Nuclear medicine, 2008, Volume: 47, Issue:3 Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Child; Hematologic Neoplasms; Humans; Neuroblastoma; Pheochromocytoma; Practice Guidelines as Topic; Tomography, Emission-Computed, Single-Photon	2008